Efficacy and safety of apatinib treatment for gastric cancer, hepatocellular carcinoma and non-small cell lung cancer: a meta-analysis

References

• KrzywinskaEKantari-MimounCKerdilesYLoss of HIF-1α in natural killer cells inhibits tumour growth by stimulating non-productive angiogenesisNat Commun201781159729150606
   PubMed Web of Science ®Google Scholar
• TianSQuanHXieCYN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivoCancer Sci201110271374138021443688
   PubMed Web of Science ®Google Scholar
• LinMISessaWCAntiangiogenic therapy: creating a unique “window” of opportunityCancer Cell20046652953115607955
   PubMed Web of Science ®Google Scholar
• WallinJJBendellJCFunkeRAtezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinomaNat Commun201671262427571927
   PubMed Web of Science ®Google Scholar
• RamjiawanRRGriffioenAWDudaDGAnti-angiogenesis for cancer revisited: is there a role for combinations with immunotherapy?Angiogenesis201720218520428361267
   PubMed Web of Science ®Google Scholar
• FontanellaCOngaroEBolzonelloSClinical advances in the development of novel VEGFR2 inhibitorsAnn Transl Med201421212325568876
   PubMedGoogle Scholar
• JiangJFChenXYZhongDFMetabolic research of domestically developed small molecule tyrosine kinase inhibitorsYao Xue Xue Bao201651224825629856578
   PubMedGoogle Scholar
• ZhangHApatinib for molecular targeted therapy in tumorDrug Des Devel Ther2015960756081
   PubMed Web of Science ®Google Scholar
• HigginsJGreenSCochrane handbook for systematic reviews of interventionsThe Cochrane Collaboration Version 5.102011 Available from: www.cochrane-handbook.orgAccessed September 5, 2018
   Google Scholar
• HigginsJPThompsonSGDeeksJJAltmanDGMeasuring inconsistency in meta-analysesBMJ2003327741455756012958120
   PubMed Web of Science ®Google Scholar
• LiJQinSXuJApatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trialJ Clin Oncol201331263219322523918952
   PubMed Web of Science ®Google Scholar
• ZhangLShiMHuangCA phase II, multicenter, placebo-controlled trial of apatinib in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after two previous treatment regimensJ Clin Oncol20123015 Suppl7548 Abstract
   Web of Science ®Google Scholar
• WangXZhangWDuWEfficacy and survival analysis of apatinib in patients with advanced nonsquamous non-small cell lung cancer after failure of first-line treatmentZhongguo Fei Ai Za Zhi2017201176176829167006
   PubMedGoogle Scholar
• GuoYJingXEfficacy and safety of docetaxel plus apatinib as a second-line treatment for advanced nonsquamous non-small cell lung cancerChinese J Clin Oncol20174411544546
   Google Scholar
• LuWJinXLYangCComparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma: a single-center randomized controlled trialCancer Biol Ther201718643343828548587
   PubMed Web of Science ®Google Scholar
• LiWManWGuoHYangPClinical research of apatinib with transcatheter arterial chemoembolization in treatment of advanced hepatocellular carcinomaAnti-Tumor Pharmacy201777478
   Google Scholar
• LiJQinSXuJRandomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junctionJ Clin Oncol201634131448145426884585
   PubMed Web of Science ®Google Scholar
• LiuCChenSWangPPreliminary study of the treatment effect of apatinib mesylate upon malignant ascites and its safetyTransl Cancer Res201765894900
   Web of Science ®Google Scholar
• MatsumotoSBatraSSaitoKAntiangiogenic agent sunitinib transiently increases tumor oxygenation and suppresses cycling hypoxiaCancer Res201171206350635921878530
   PubMed Web of Science ®Google Scholar
• TangJRMarkhamNELinYJInhaled nitric oxide attenuates pulmonary hypertension and improves lung growth in infant rats after neonatal treatment with a VEGF receptor inhibitorAm J Physiol Lung Cell Mol Physiol20042872L344L35115064225
   PubMed Web of Science ®Google Scholar
• Launay-VacherVDerayGHypertension and proteinuria: a class-effect of antiangiogenic therapiesAnticancer Drugs2009201818219343005
   PubMed Web of Science ®Google Scholar
• LiuXQinSWangZEarly presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort studyJ Hematol Oncol201710115328870253
   PubMed Web of Science ®Google Scholar
• KouPZhangYShaoWSignificant efficacy and well safety of apatinib in an advanced liver cancer patient: a case report and literature reviewOncotarget2017812205102051528103584
   PubMedGoogle Scholar
• PengYCuiHLiuZApatinib to combat EGFR-TKI resistance in an advanced non-small cell lung cancer patient with unknown EGFR status: a case reportOnco Targets Ther2017102289229528490886
   PubMed Web of Science ®Google Scholar
• DengLWangYLuWApatinib treatment combined with chemotherapy for advanced epithelial ovarian cancer: a case reportOnco Targets Ther2017101521152528352185
   PubMed Web of Science ®Google Scholar
• KangYKBokuNKangWKA prospective, randomized, double-blinded, placebo-controlled, phase III study to evaluate the efficacy and safety of apatinib plus best supportive care (BSC) compared to placebo plus BSC in patients with advanced or metastatic gastric cancer: the ANGEL studyJ Clin Oncol20173515_supplTPS4138 Abstract
   Web of Science ®Google Scholar
• LinYWangKHuCElemene injection induced autophagy protects human hepatoma cancer cells from starvation and undergoing apoptosisEvid Based Complement Alternat Med2014201463752825152762
   PubMed Web of Science ®Google Scholar